Aldeyra Therapeutics, Inc. (ALDX) Financial Statements
Free cash flow over the same period: -$22.0M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
ALDXAldeyra Therapeutics, Inc.Follow ALDX — free
—
Price chart with a free account
- Market cap
- 39.2M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2014 Dec 14 | FY2015 Dec 15 | FY2016 Dec 16 | FY2017 Dec 17 | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research & development | 3.7 | 7.6 | 13.2 | 16.3 | 29.8 | 44.4 | 24.7 | 44.9 | 47.3 | 29.5 | 48.2 | 25.7 | 15.6 | |
| Operating income | -7.3 | -12.0 | -18.7 | -22.5 | -39.7 | -63.1 | -36.4 | -56.2 | -62.7 | -42.8 | -60.1 | -35.3 | -24.1 | |
| Pre-tax income | -5.2 | -12.1 | -18.7 | -22.3 | -38.9 | -62.1 | -38.0 | -57.8 | -62.0 | -37.5 | -55.9 | -33.8 | -23.1 | |
| Income tax | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | -1.3 | -0.5 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | |
| Net income | -5.2 | -12.1 | -18.7 | -22.3 | -38.9 | -60.8 | -37.6 | -57.8 | -62.0 | -37.5 | -55.9 | -33.8 | -23.1 | |
| Diluted EPS ($) | -3.09 | -1.40 | -1.65 | -1.40 | -1.79 | -2.24 | -1.11 | -1.07 | -1.06 | -0.64 | -0.94 | -0.56 | -0.38 | |
| Diluted shares (mn) | 3.9 | 8.6 | — | — | — | — | — | 54.0 | 58.4 | 58.9 | 59.5 | 60.1 | — |
USD millions · SEC XBRL
Aldeyra Therapeutics, Inc. — questions
- What is Aldeyra Therapeutics, Inc.'s net income?
- -$23.1M over the twelve months to 2026-06-30.
- What is Aldeyra Therapeutics, Inc.'s free cash flow?
- -$22.0M over the twelve months to 2026-06-30.
- What are Aldeyra Therapeutics, Inc.'s diluted earnings per share?
- $-0.38 over the twelve months to 2026-06-30.
Every figure on this page comes from Aldeyra Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.